In the DAPPER phase II trial (NCT03851614), patients with MSS CRC, pancreatic adenocarcinoma, or leiomyosarcoma were randomized to receive a combination of durvalumab (anti PD-1) plus olaparib or cediranib (VEGF1-3 inhibitor). This evidence concerns the gene PDCD1 and colorectal carcinoma.